Hematological Cancer
Show only recruiting trials?

ALC.6 | A041501
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Status
Recruiting
JCP
ALC.6
NCT
NCT03150693

LY.18 (ML40080, A17-190)
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Status
Opening Soon
JCP
LY18
NCT
NCT04161248

LY.16
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)
Status
Closed to Accrual
JCP
LY.16
NCT
NCT01650701

P16-489 | DEVOTE
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)
Status
Closed to Accrual
JCP
Devote
NCT
NCT03310190
Filter Clinical Trials by:
Biomarkers: